Related Experiment Videos
Latanoprost exposure in pregnancy
Marco De Santis1, Angela Lucchese, Brigida Carducci
1Telefono Rosso Teratology Information Service, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. marcodesantis@rm.unicatt.it
American Journal of Ophthalmology
|August 4, 2004
Summary
This study found no evidence of adverse effects in nine pregnancies exposed to latanoprost, a glaucoma medication, during the first trimester. Further research is needed due to the small sample size.
Area of Science:
- Ophthalmology
- Reproductive Medicine
- Pharmacology
Background:
- Latanoprost, a prostaglandin analog for glaucoma, has limited use in pregnancy due to animal study findings.
- Animal studies indicate a high incidence of abortion with latanoprost.
- Human data on latanoprost exposure during pregnancy is inadequate, leading to its FDA Category C classification.
Purpose of the Study:
- To observe pregnancy outcomes following latanoprost exposure.
- To evaluate fetal effects in pregnancies exposed to latanoprost during the first trimester.
Main Methods:
- Observational study design.
- Data collected via a Teratology Information Service.
- Prospective follow-up of pregnant women through phone interviews.
Main Results:
- Eleven cases of latanoprost exposure during pregnancy were identified.
- One case resulted in miscarriage; one was lost to follow-up.
- Nine cases completed follow-up with no reported congenital anomalies.
Conclusions:
- The study series is too small for statistical significance.
- No evidence of adverse effects on pregnancy or neonatal outcomes was observed with latanoprost exposure.